Sanofi Companies

 
Stock Quotes for Sanofi Companies top ^
  • Industry: Drug Manufacturers - Specialty & Generic
  • Sector: Healthcare
  • Stock Style: Large Value
  • Morningstar Rating: 4 Stars
Sign-up for sny investment picks
  • Industry: Drug Manufacturers - Specialty & Generic
  • Sector: Healthcare
  • Stock Style: Large Value
  • Morningstar Rating: 4 Stars
Sign-up for san investment picks
  • Industry: Drug Manufacturers - Major
  • Sector: Healthcare
  • Stock Style: Mid Growth
Sign-up for 500674 investment picks
  • Industry: Drug Manufacturers - Specialty & Generic
  • Sector: Healthcare
  • Stock Style: Large Value
  • Morningstar Rating: 4 Stars
Sign-up for sny investment picks

 
News Articles for Sanofi Companies top ^
PARIS, April 7, 2014 (GLOBE NEWSWIRE) -- Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today that following constructive discussions with the U.S. Food and Drug Administration (FDA) the company plans to resubmit in the second quarter its supplemental Biologics License Application (sBLA) seeking approval of Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis.
Sign-up for Sanofi: Genzyme to Resubmit Lemtrada Application for FDA Review investment picks
Slowing of Brain Atrophy and Reductions in New Multiple Sclrosis Lesions Sustained at Three Years in Patients Treated with Genzyme's Lemtrada TM - Consistent effects seen across key MRI measures of disease activity; Effects were sustained beyond two-year pivotal MS studies - - Approximately 80 percent of patients treated with Lemtrada did not receive a third course of treatment in the first year of the extension - PARIS, April 30, 2014 (GLOBE NEWSWIRE) -- Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today new magnetic resonance imaging (MRI) data from the Lemtrada (alemtuzumab) clinical development program.
Sign-up for Sanofi: Slowing of Brain Atrophy and Reductions in New MS Lesions Sustained at Three Years in Patients Treated with Genzyme's Lemtrada investment picks
ANN ARBOR, Mich., April 21, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) , the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that it has entered into a definitive agreement to acquire Sanofi's Cell Therapy and Regenerative Medicine (CTRM) business for a purchase price of $6.5 million, with $4 million payable in cash at closing and $2.5 million payable in the form of a promissory note.
Sign-up for Aastrom Announces Definitive Agreement to Acquire Sanofi's Cell Therapy and Regenerative Medicine Business investment picks
2014/4/29
PARIS , April 29, 2014 /PRNewswire/ -- Sanofi, a global and diversified healthcare leader, reports results for the first-quarter of 2014.
Sign-up for Sanofi Q1 2014 Results - Interview with CFO Jérôme Contamine investment picks
2014/4/25
PARIS, April 25, 2014 (GLOBE NEWSWIRE) -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced on World Malaria Day that 300 million treatments of anti-malarial ASAQ Winthrop ® have been delivered in Africa since the medication became available in 2007.
Sign-up for SANOFI : Sanofi Reaches New Milestone in Fight Against Malaria: 300 million ASAQ Treatments Delivered in Africa investment picks
LONDON (MarketWatch) -- Allergan Inc. (AGN) has approached Sanofi (fr:san), Johnson & Johnson (JNJ) and other companies to gauge their interest in acquiring the Botox maker, Bloomberg reported Tuesday, citing people with knowledge of the matter.
Sign-up for Allergan looks to Sanofi, J&J for takeover: report investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Sanofi Companies
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Sandridge Energy  |  Next: Savanna Energy Services